Permeasis Therapeutics and The Ohio State University Publish Foundational Research on Intracellular Delivery Technology in ACS Chemical Biology
Permeasis Therapeutics (“Permeasis”), a biotechnology company developing intracellular biologics enabled by its proprietary Membrane Translocation Domain (MTD) platform announced the publication of foundational research describing the MTD platform in ACS Chemical Biology. The peer-reviewed study, led by researchers at The Ohio State University and Permeasis, demonstrates the ability of the platform to transport peptides and proteins directly into cells, potentially overcoming one of the most significant barriers in modern drug development.
